Clinical Trial Update: PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) [Phase 2]

View source ↗

Summary

This entry notes a Phase 2 clinical trial of an oral hexavalent reassortant rotavirus vaccine (attenuated live, Vero cells) by Sinovac Life Sciences Co., Ltd., …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Gastroenteritis

Drugs mentioned

• Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

Snippet

Sponsor: Sinovac Life Sciences Co., Ltd. | Conditions: Rotavirus Gastroenteritis | Phase 2 | Status: RECRUITING